uniQure (NASDAQ:QURE) Shares Gap Up After Analyst Upgrade

uniQure N.V. (NASDAQ:QURE) shares gapped up prior to trading on Monday after Royal Bank Of Canada upgraded the stock from a sector perform rating to an outperform rating. The stock had previously closed at $14.27, but opened at $18.02. Royal Bank Of Canada now has a $35.00 price target on the stock, up from their previous price target of $11.00. uniQure shares last traded at $16.1640, with a volume of 5,988,132 shares changing hands.

QURE has been the topic of a number of other research reports. Barclays assumed coverage on uniQure in a research report on Tuesday, January 27th. They issued an “equal weight” rating and a $31.00 target price on the stock. Mizuho reiterated a “neutral” rating and set a $12.00 price target (down from $33.00) on shares of uniQure in a report on Tuesday, March 3rd. Wells Fargo & Company upgraded shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $15.00 to $60.00 in a report on Monday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Finally, The Goldman Sachs Group lowered their target price on shares of uniQure from $37.00 to $9.00 and set a “neutral” rating for the company in a research note on Tuesday, March 3rd. Nine investment analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $40.08.

Insider Transactions at uniQure

In other uniQure news, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the transaction, the director owned 32,342 shares in the company, valued at $796,260.04. The trade was a 44.19% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of the stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $132,103.86. Following the completion of the sale, the chief executive officer directly owned 660,658 shares in the company, valued at approximately $5,985,561.48. This represents a 2.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 81,399 shares of company stock valued at $1,527,645 over the last quarter. Insiders own 4.79% of the company’s stock.

uniQure News Summary

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Wells Fargo upgraded uniQure from Equal Weight to Overweight and raised its price target to $60, signaling strong upside expectations from one large shop. Read More.
• Positive Sentiment: Royal Bank of Canada upgraded uniQure from Sector Perform to Outperform with a $35 price target — another sizable upward re‑rating that supports the rally.
• Positive Sentiment: Market reaction tied to the exit of a senior FDA/CBER official (reported as a catalyst); investors interpret the departure as reducing near‑term regulatory risk around the AMT‑130 Huntington’s program. Read More.
• Neutral Sentiment: News roundups explain the surge and market reaction but add little new data — useful for context but not a driver by itself. Read More.
• Neutral Sentiment: Broader market weakness in futures could cap upside or increase intraday volatility for biotech names including QURE. Read More.
• Negative Sentiment: Regulatory dispute around AMT‑130 remains unresolved and media coverage describes growing confusion and public rebukes — this raises the chance of additional trials/delays that could materially damage the therapy’s timeline and valuation. Read More.
• Negative Sentiment: Several law firms have filed or solicited class‑action claims and are reminding shareholders of a lead‑plaintiff deadline (April 13, 2026), introducing legal risk and potential management distraction. Read More.
• Negative Sentiment: Insider selling (disclosed early March) and prior analyst cuts/negative coverage remain a headwind and could limit sustained upside absent clear regulatory progress. Read More.
• Negative Sentiment: Earlier public criticism from FDA officials characterizing the Huntington’s program as unsuccessful underpins the regulatory risk that sparked the prior selloff; that risk has not been fully resolved. Read More.

Hedge Funds Weigh In On uniQure

Large investors have recently bought and sold shares of the business. Private Trust Co. NA purchased a new stake in uniQure during the 3rd quarter worth about $28,000. Jones Financial Companies Lllp increased its holdings in shares of uniQure by 509.0% in the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 509 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of uniQure by 5.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 10,150 shares of the biotechnology company’s stock valued at $243,000 after acquiring an additional 533 shares during the last quarter. Arizona State Retirement System raised its position in shares of uniQure by 6.0% during the 4th quarter. Arizona State Retirement System now owns 11,141 shares of the biotechnology company’s stock worth $267,000 after acquiring an additional 627 shares in the last quarter. Finally, Ensign Peak Advisors Inc raised its position in shares of uniQure by 21.7% during the 4th quarter. Ensign Peak Advisors Inc now owns 3,650 shares of the biotechnology company’s stock worth $87,000 after acquiring an additional 650 shares in the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

The firm has a 50 day moving average of $22.04 and a two-hundred day moving average of $29.63. The stock has a market cap of $1.02 billion, a PE ratio of -4.73 and a beta of 0.73. The company has a debt-to-equity ratio of 0.25, a current ratio of 10.43 and a quick ratio of 10.43.

uniQure (NASDAQ:QURE) last announced its quarterly earnings results on Monday, March 2nd. The biotechnology company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The company had revenue of $5.57 million for the quarter, compared to analyst estimates of $4.84 million. Research analysts predict that uniQure N.V. will post -3.75 EPS for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.